Critical care aspects of lung transplantation

Journal of Intensive Care Medicine

Volumn 19, Issue 2, 2004, Pages 83-104

  Lau, Christine L ^a   Patterson, G Alexander ^a   Palmer, Scott M ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Critical care; Immunosuppressive agents; Lung transplant; Postoperative complications

Indexed keywords

BRONCHIOLITIS OBLITERANS; CHRONIC GRAFT REJECTION; GRAFT RECIPIENT; HISTOCOMPATIBILITY; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; LUNG INSUFFICIENCY; LUNG TRANSPLANTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE; SURVIVAL TIME; CHRONIC DISEASE; CROSS INFECTION; DONOR; GRAFT REJECTION; HYPERAMMONEMIA; IMMUNOLOGY; KIDNEY FAILURE; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MORTALITY; PATIENT SELECTION; PERIOPERATIVE PERIOD; REPERFUSION INJURY; STATISTICS; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL RATE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TIME; TRANSPLANTATION; TREATMENT OUTCOME;

IMMUNOSUPPRESSIVE AGENT;

BRONCHIOLITIS OBLITERANS; CHRONIC DISEASE; CRITICAL CARE; CROSS INFECTION; GRAFT REJECTION; HUMANS; HYPERAMMONEMIA; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE; LUNG TRANSPLANTATION; METABOLIC CLEARANCE RATE; PATIENT SELECTION; PERIOPERATIVE CARE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REPERFUSION INJURY; SURVIVAL RATE; TACHYCARDIA, ECTOPIC ATRIAL; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; TREATMENT OUTCOME;

EID: 2342426163     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066603261509     Document Type: Review

References (133)

1. Toronto Lung Transplantation Group. Unilateral lung transplantation for pulmonary fibrosis. N Engl J Med. 1986;314:1140-1145.
2. Trulock EP, Edwards LB, Taylor DO, et al. The registry of the International Society for Heart and Lung Transplantation: twentieth official adult lung and heart-lung transplant report-2003. J Heart Lung Transplant. 2003;22:625-635.
3. Egan TM, Bennett LE, Garrity ER, et al. Predictors of death on the UNOS lung transplant waiting list results of a muti-variate analysis. J Heart Lung Transplant. 2001;20:242A.
4. De Meester J, Smits JM, Persijn GG, Haverich A. Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience. J Heart Lung Transplant. 2001;20:518-524.
5. Hosenpud JD, Bennett LE, Keck BM, et al. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet. 1998;351:24-27.
6. Charman SC, Sharples LD, McNeil KD, Wallwork J. Assessment of survival benefit after lung transplantation by patient diagnosis. J Heart Lung Transplant. 2002;21:226-232.
7. Sundaresan S, Trachiotis GD, Aoe M, et al. Donor lung procurement: assessment and operative technique. Ann Thorac Surg. 1993;56:1409-1413.
8. Straznicka M, Follette DM, Eisner MD, et al. Aggressive management of lung donors classified as unacceptable: excellent recipient survival one year after transplantation. J Thorac Cardiovasc Surg. 2002;124:230-258.
9. Follette DM, Rudich SM, Babcock WD. Improved oxygenation and increased lung donor recovery with high-dose steroid administration after brain death. J Heart Lung Transplant. 1998;17:423-429.
10. Cummings J, Houck J, Lichtenfeld D. Positive effect of aggressive resuscitative efforts on cadaver lung procurement. J Transplant Coordination. 1995;5:103-106.
11. Steen S, Sjoberg T, Pierre L, et al. Transplantation of lungs from a non-heart-beating donor. Lancet. 2001;357:825-829.
12. Palmer SM, Layish DT, Kussin PS, et al. Lung transplantation for Williams-Campbell syndrome. Chest. 1998;113:534-537.
13. Meyers BF, Lynch JP, Trulock EP, et al. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-year institutional experience. J Thorac Cardiovasc Surg. 2000;120:99-107.
14. Cooper JD, Pearson FG, Patterson GA, et al. Technique of successful lung transplantation in humans. J Thorac Cardiovasc Surg. 1987;93:173-181.
15. Pasque MK, Trulock EP, Cooper JD, et al. Single lung transplantation for pulmonary hypertension: single institution experience in 34 patients. Circulation. 1995;92:2252-2258.
16. Davis RD, Trulock EP, Manley J, et al. Differences in early results after single lung transplantation. Ann Thorac Surg. 1994;58:1327-1335.
17. Hadjiliadis D, Sporn TA, Perfect JR, et al. Outcome of lung transplantation in patients with mycetomas. Chest. 2002;121:128-134.
18. Cassivi SD, Meyers BF, Battafarano RJ, et al. Thirteen-year experience in lung transplantation for emphysema. Ann Thorac Surg. 2002;74:1663-1669.
19. Hadjiliadis D, Davis RD, Palmer SM. Is transplant operation important in determining posttransplant risk of bronchiolitis obliterans syndrome in lung transplant recipients? Chest. 2002;122:1168-1175.
20. Huddleston CB, Bloch JB, Sweet SC, et al. Lung transplantation in children. Ann Surg. 2002;236:270-276.
21. Pochettino A, Bavaria JE. Anterior axillary muscle-sparing thoracotomy for lung transplantation. Ann Thorac Surg. 1997;64:1846-1848.
22. Meyers BF, Lynch J, Trulock EP, et al. Lung transplantation: a decade of experience. Ann Surg. 1999;230:362-370; discussion, 370-361.
23. Sugita M, Ferraro P, Dagenais A, et al. Alveolar liquid clearance and sodium channel expression are decreased in transplanted canine lungs. Am J Respir Crit Care Med. 2003;167:1440-1450.
24. Triantafillou AN, Heerdt PM, Hogue CW, et al. Epidural vs intravenous morphine for postoperative pain management after lung transplantation. Anesthesiology. 1992;77:A858.
25. Matsuzaki Y, Waddell TK, Puskas JD, et al. Amelioration of post-ischemic lung reperfusion injury by PGE1. Am Rev Respir Dis. 1993;148:882-889.
26. Keshavjee S, Yamazaki F, Cardoso PF, et al. A method for safe twelve-hour pulmonary preservation. J Thorac Cardiovasc Surg. 1989;98:529-534.
27. Maccherini M, Keshavjee SH, Slutsky AS, et al. The effect of low-potassium-dextran versus Euro-Collins solution for preservation of isolated type II pneumocytes. Transplantation. 1991;52:621-626.
28. Fischer S, Matte-Martyn A, De Perrot M, et al. Low-potassium dextran presentation solution improves lung function after human lung transplantation. J Thorac Cardiovasc Surg. 2001;121:594-596.
29. Yamashita M, Schmid RA, Ando K, et al. Nitroprusside ameliorates lung allograft reperfusion injury. Ann Thorac Surg. 1996;62:791-797.
30. Halldorsson A, Kronon M, Allen BS, et al. Controlled reperfusion prevents pulmonary injury after 24-hours of lung preservation. Ann Thorac Surg. 1998;66:877-884; discussion, 884-885.
31. Halldorsson A, Kronon M, Allen BS, et al. Controlled reperfusion after lung ischemia: implications for improved function after lung transplantation. J Thorac Cardiovasc Surg. 1998;115:415-425.
32. Clark SC, Sudarshan C, Khanna R, et al. Controlled reperfusion and pentoxifylline modulates reperfusion injury after single lung transplantation. J Thorac Cardiovasc Surg.
33. Bhabra MS, Hopkinson DN, Shaw TE, et al. Controlled reperfusion protects lung grafts during a transient early increase in permeability. Ann Thorac Surg. 1998;65:187-192.
34. Halldorsson AO, Kronon MT, Allen BS, et al. Lowering reperfusion pressure reduces the injury after pulmonary ischemia. Ann Thorac Surg. 2000;69:198-203.
35. Clark SC, Sudarshan CD, Dark JH. Controlled perfusion of the transplanted lung. Ann Thorac Surg. 2001;71:1755-1756.
36. Fiser SM, Kron IL, Long SM, et al. Controlled perfusion decreases reperfusion injury after high-flow reperfusion. J Heart Lung Transplant. 2002;21:687-691.
37. Lick SD, Brown PS Jr, Kurusz M, et al. Technique of controlled reperfusion of the transplanted lung in humans. Ann Thorac Surg. 2000;69:910-912.
38. Date H, Triantafillou A, Trulock E, et al. Inhaled nitric oxide reduces human lung allograft dysfunction. J Thorac Cardiovasc Surg. 1996;111:913-919.
39. Fiser SM, Cope JT, Kron IL, et al. Aerosolized prostacyclin (epoprostenol) as an alternative to inhaled nitric oxide for patients with reperfusion injury after lung transplantation [published correction appears in J Thorac Cardiovasc Surg. 2001;121:1136]. J Thorac Cardiovasc Surg. 2001;121:981-982.
40. Meyers BF, Sundt TM III, Henry S, et al. Selective use of extracorporeal membrane oxygenation is warranted after lung transplantation. J Thorac Cardiovasc Surg. 2000;120:20-26.
41. Mal N, Andreassian B, Pamela F, et al. Unilateral lung transplantation in end-stage pulmonary emphysema. Am Rev Respir Dis. 1989;140:797-802.
42. Popple C, Higgins TL, McCarthy P, et al. Unilateral auto-PEEP in the recipient of a single lung transplant. Chest. 1993;103:297-299.
43. Gavazzeni V, Iapichino G, Mascheroni D, et al. Prolonged independent lung respiratory treatment after single lung transplantation in pulmonary emphysema. Chest. 1993;103:96-100.
44. Patterson GA, Todd TR, Cooper JD, et al. Airway complications after double lung transplantation. J Thorac Cardiovasc Surg. 1990;99:14-21.
45. Date H, Trulock EP, Arcidi JM, et al. Improved airway healing after lung transplantation: an analysis of 348 bronchial anastomoses. J Thorac Cardiovasc Surg. 1995;110:1424-1433.
46. King-Biggs MB, Dunitz JM, Park SJ, et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation. 2003;75:1437-1443.
47. Susanto I, Peters JI, Levine SM, et al. Use of balloon-expandable metallic stents in the management of bronchial stenosis and bronchomalacia after lung transplantation. Chest. 1998;114:1330-1335.
48. Chhajed PJ, Malouf MM, Tamm M, et al. Interventional bronchoscopy for the management of airway complications following lung transplantation. Chest. 2001;120:1894-1899.
49. Chaparro C, Kesten S. Infections in lung transplant recipients. Clin Chest Med. 1997;18:339-351.
50. Bassiri AG, Girgis RE, Theodore S. Actinomyces odontolyticus thoracopulmonary infections. Two cases in lung and heart-lung transplant recipients and review of the literature. Am J Respir Crit Care Med. 1995;152:374-376.
51. Palmer SM, Alexander BD, Sanders LL, et al. Significance of blood stream infection after lung transplantation: analysis in 176 consecutive patients. Transplantation. 2000;69:2360-2366.
52. Ettinger NA, Bailey TC, Trulock EP, et al. Cytomegalovirus infection and pneumonitis. Impact after isolation lung transplantation. Am Rev Respir Dis. 1993;147:1017-1023.
53. Gutierrez CA, Chaparro C, Drajden M, et al. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest. 1998;113:924-932.
54. Kruger RM, Paranjothi S, Storch GA, et al. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients. J Heart Lung Transplant. 2003;22:754-763.
55. Zamora MR. Controversies in lung transplantation: management of cytomegalovirus infections. J Heart Lung Transplant. 2002;21:841-849.
56. Zedtwitz-Liebenstein K, Presterl E, Deviatko E, Graninger W. Acute renal failure in a lung transplant patient after therapy with cidofovir. Transplant Int. 2001;14:445-446.
57. Palmer SM Jr, Henshaw NG, Howell DX, et al. Community respiratory viral infection in adult lung transplant recipients. Chest. 1998;113:944-950.
58. Holt ND, Gould FK, Taylor CE, et al. Incidence and significance of noncytomegalovirus viral respiratory infection after adult lung transplantation. J Heart Lung Transplant. 1997;16:416-419.
59. Matar LD, McAdams HP, Palmer SM, et al. Respiratory viral infections in lung transplant recipients: radiologic findings with clinical correlation. Radiology. 1999;213:735-742.
60. Garantziotis S, Howell DN, McAdams HP, et al. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest. 2001;119:1277-1280.
61. McCurdy LH, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant. 2003;22:745-753.
62. Bridges ND, Spray TL, Collins MH, et al. Adenovirus infection in the lung results in graft failure after lung transplantation. J Thorac Cardiovasc Surg. 1998;116:617-623.
63. Blumberg EA, Albano C, Pruett T, et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis. 1996;22:295-302.
64. Wandstrat TL. Respiratory syncytial virus immune globulin intravenous. Ann Pharmacother. 1997;31:83-88.
65. Zahradnik JM. Adenovirus pneumonia. Semin Respir Infect. 1987;2:104-111.
66. Jurado M, Navarro JM, Hernandez J, et al. Adenovirus-associated haemorrhagic cystitis after bone marrow transplantation successfully treated with intravenous ribavirin. Bone Marrow Transplant. 1995;15:651-652.
67. McCarthy AJ, Bergin M, De Silva LM, Stevens M. Intravenous ribavirin therapy for disseminated adenovirus infection. Pediatr Infect Dis J. 1995;14:1003-1004.
68. Maslo C, Girard PM, Urban T, et al. Ribavirin therapy for adenovirus pneumonia in an AIDS patient. Am J Respir Crit Care Med. 1997;156:1263-1264.
69. Shetty AK, Gans HA, So S, et al. Intravenous ribavirin therapy for adenovirus pneumonia. Pediatr Pulmonology. 2000;29:69-73.
70. Cox NJ, Subbarao K. Influenza. Lancet. 1999;354:1277-1282.
71. Anonymous. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group [published correction appears in Lancet. 1999;353:504]. Lancet. 1998;352:1877-1881.
72. Dengler TJ, Strnad N, Buhring I, et al. Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Transplantation. 1998;66:1340-1347.
73. Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine. 1996;75:142-156.
74. Mehrad B, Paciocco G, Martinez FJ, et al. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest. 2001;119:169-175.
75. Kramer MR, Denning DW, Marshall SE, et al. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis. 1991;144:552-556.
76. Nunley DR, Gal AA, Vega JD, et al. Saprophytic fungal infections and complications involving the bronchial anastomosis following human lung transplantation. Chest. 2002;122:1185-1191.
77. Palmer SM, Perfect JR, Howell DN, et al. Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. J Heart Lung Transplant. 1998;17:1029-1033.
78. Hadjiliadis D, Howell DN, Davis RD, et al. Anastomotic infections in lung transplant recipients. Ann Transplant. 2000;5:13-19.
79. Westney GE, Kesten S, DeHoyos A, et al. Aspergillus infection in single and double lung transplant recipients. Transplantation. 1996;61:915-919.
80. Nunley DR, Grgurich W, Iacono AT, et al. Allograft colonization and infections with pseudomonas in cystic fibrosis lung transplant recipients. Chest. 1998;113:1235-1243.
81. Husain S, McCurry K, Dauber J, et al. Nocardia infection in lung transplant recipients. J Heart Lung Transplant. 2002;21:354-359.
82. Palmer SM, Kanj SS, Davis RD, Tapson VF. A case of disseminated infection with Nocardia brasillensis in a lung transplant recipient. Transplantation. 1997;63:1189-1190.
83. Raj R, Frost AE. Scedosporium apiospermum fungemia in a lung transplant recipient. Chest. 2002;121:1714-1716.
84. Calvo V, Borro JM, Morales P, et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest. 1999;115:1301-1304.
85. Erjavec Z, Woolthuis GM, de Vries-Hospers HG, et al. Tolerance and efficacy of Amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis. 1997;16:364-368.
86. Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation. 2001;72:545-548.
87. Nunley DR, Grgurich WF, Keenan RJ, Dauber JH. Empyema complicating successful lung transplantation. Chest. 1999;115:1312-1315.
88. Frost AE, Jammal CT, Cagle PT. Hyperacute rejection following lung transplantation. Chest. 1996;110:559-562.
89. Bittner HB, Dunitz J, Hertz M, et al. Hyperacute rejection in single lung transplantation-case report of successful management by means of plasmapheresis and antithymocyte globulin treatment. Transplantation. 2001;71:649-651.
90. Choi JK, Kearns J, Palevsky HI, et al. Hyperacute rejection of a pulmonary allograft. Immediate clinical and pathologic findings. Am J Respir Crit Care Med. 1999;160:1015-1018.
91. Martin GAS, Reddy VB, Garrity DR, et al. Humoral (antibody-mediated) rejection in lung transplantation. J Heart Lung Transplant. 1996;15:1217-1222.
92. Lau CL, Palmer SM, Posther KE, et al. Influence of panel-reactive antibodies on posttransplant outcomes In lung transplant recipients. Ann Thorac Surg. 2000;69:1520-1524.
93. Magro CM, Deng A, Pope-Harman A, et al. Humorally mediated posttransplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: a hypothesis [published correction appears in Transplantation. 2003;76:1009]. Transplantation. 2002;74:1273-1280.
94. Husain AN, Siddiqui MT, Holmes EW, et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 1999;159:829-833.
95. Hopkins PM, Aboyoun CL, Chhajed PN, et al. Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant. 2002;21:1062-1067.
96. Yousem SA, Berry GJ, Brunt EM, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: lung rejection study group. J Heart Lung Transplant. 1990;9:593-601.
97. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: lung rejection study group. J Heart Lung Transplant. 1996;15:1-15.
98. Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant. 2002;21:271-281.
99. Trulock EP, Ettinger NA, Brunt EM, et al. The role of transbronchial lung biopsy in the treatment of lung transplant recipients: an analysis of 200 consecutive procedures. Chest. 1992;102:1049-1054.
100. Higenbottam T, Stewart S, Penketh A, Wallwork J. Transbronchial lung biopsy for the diagnosis of rejection in heart-lung transplant patients. Transplant. 1988;46:532-539.
101. Sibley RK. The role of transbronchial biopsies in the management of lung transplant recipients. J Heart Lung Transplant. 1993;12:308-324.
102. Boehler A, Vogt P, Zollinger A, et al. Prospective study of the value of transbronchial lung biopsy after lung transplantation. Eur Respir J. 1996;9:658-662.
103. Guilinger RA, Paradis IL, Dauber JH, et al. The importance of bronchoscopy with transbronchial biopsy and bronchoalveolar lavage in the management of lung transplant recipients. Am J Respir Crit Care Med. 1995;152:2037-2043.
104. Baz MA, Layish DT, Govert JA, et al. Diagnostic yield of bronchoscopies after isolated lung transplantation. Chest. 1996;110:84-88.
105. Tamm M, Sharples LD, Higenbottam TW, et al. Bronchiolitis obliterans syndrome in heart-lung transplantation: surveillance biopsies. Am J Respir Crit Care Med. 1997;155:1705-1710.
106. Valentine VG, Taylor DE, Dhillon GS, et al. Success of lung transplantation without surveillance bronchoscopy. J Heart Lung Transplant. 2002;21:319-326.
107. Brock MV, Borja MC, Ferber L, et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant. 2001;20:1282-1290.
108. Trulock EP. Lung transplantation. Am J Respir Crit Care Med. 1997;155:789-818.
109. Vitulo P, Oggionni T, Cascina A, et al. Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation. J Heart Lung Transplant. 2002;21:435-439.
110. Horning NR, Lynch JP, Sundaresan SR, et al. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. J Heart Lung Transplant. 1998;17:761-767.
111. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet. 2000;356:194-202.
112. Hong JC, Kahan BD. Sirolimus rescue therapy for refractory rejection in renal transplantation. Transplantation. 2001;71:1579-1584.
113. Snell GI, Levvey BJ, Chin W, et al. Rescue therapy: a role for sirolimus in lung and heart transplant recipients. Transplant Proc. 2001;33:1084-1085.
114. Williams JW, Mital D, Chong A, et al. Experiences with leflunomide in solid organ transplantation. Transplantation. 2002;73:358-366.
115. Chakinala MM, Trulock EP. Acute allograft rejection after lung transplantation: diagnosis and therapy. Chest Clin N Am. 2003;13:525-542.
116. ISHLT, Cooper JD, Billingham M, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant. 1993;12:713-716.
117. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002;21:297-310.
118. Hertz MI, Taylor DO, Trulock EP, et al. The registry of the international society for heart and lung transplantation: nineteenth official report-2002. J Heart Lung Transplant. 2002;21:950-970.
119. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med. 2002;166:440-444.
120. Davis RD, Lau CL, Eubanks S, et al. Improved lung allograft function following fundoplication in lung transplant patients with GERD. J Thorac Cardiovasc Surg. 2003;125:533-542.
121. Lubetkin EI, Lipson DA, Palevsky HI, et al. GI complications after orthotopic lung transplantation. AJG. 1996;91:2382-2390.
122. Hoekstra HJ, Hawkins K, de Doer WJ, et al. Gastrointestinal complications in lung transplant survivors that require surgical intervention. Br J Surg. 2001;88:433-438.
123. Pollard TR, Schwesinger WH, Sako EY, Sirinek KR. Abdominal operations after lung transplantation. Arch Surg. 1997;12:714-718.
124. Ishani A, Erturk S, Hertz MI, et al. Predictors of renal function following lung or heart-lung transplantation. Kidney Int. 2002;61:2228-2234.
125. Soccal PM, Gasche Y, Favre H, et al. Improvement of drug-induced chronic renal failure in lung transplantation. Transplantation. 1999;68:164-165.
126. Broekroelofs J, Navis GJ, Stegeman CA, et al. Long-term renal outcome after lung transplantation is predicted by the 1-month postoperative renal function loss. Transplantation. 2000;69:1624-1628.
127. Lichtenstein GR, Yang YX, Nunes FA, et al. Fatal hyperammonemia after orthotopic lung transplantation. Ann Intern Med. 2000;132:283-287.
128. Lichtenstein GR, Kaiser LR, Tuchman M, et al. Fatal hyperammonemia following orthotopic lung transplantation. Gastroenterology. 1997;112:236-240.
129. Tuchman M, Lichtenstein GR, Rajagopal BS, et al. Hepatic glutamine synthetase deficiency in fatal hyperammonemia after lung transplantation. Ann Intern Med. 1997;127:446-449.
130. Berry GT, Bridges ND, Nathanson KL, et al. Successful use of alternate waste nitrogen agents and hemodialysis in a patient with hyperammonemic coma after heart-lung transplantation. Arch Neurol. 1999;56:481-484.
131. Singh N, Gayowski T, Marino IR. Hemolytic uremic syndrome in solid-organ transplant recipients. Transplant Int. 1996;9:68-75.
132. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood. 2000;96:1223-1229.
133. Chakinala MM, Kollef MH, Trulock EP. Critical care aspects of lung transplant patients. J Intensive Care Med. 2002;17:8-33.